Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S9WB
|
|||
| Drug Name |
Lumacaftor + ivacaftor
|
|||
| Indication | Acute lung injury [ICD-11: NB32.3; ICD-10: S27.3] | Approved | [1] | |
| Cystic fibrosis [ICD-11: CA25; ICD-10: E84, E84.9; ICD-9: 277] | Approved | [1] | ||
| Company |
Vertex
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | cAMP-dependent chloride channel (CFTR) | Target Info | Enhancer | [1] |
| cAMP-dependent chloride channel F508 deletion (CFTR del F508) | Target Info | Enhancer | [1] | |
| KEGG Pathway | ABC transporters | |||
| cAMP signaling pathway | ||||
| AMPK signaling pathway | ||||
| Gastric acid secretion | ||||
| Pancreatic secretion | ||||
| Bile secretion | ||||
| Vibrio cholerae infection | ||||
| Reactome | ABC-family proteins mediated transport | |||
| WikiPathways | ABC-family proteins mediated transport | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.